Mentions in the News
FDA Green-Lighting Drugs at Breakneck Speed -- and Raising Alarm...
The U.S. is approving new drugs so fast that companies are now preparing for a green light months in advance of the scheduled decision date, a pace that’s helping patients with rare or untreatable diseases but raising alarm among consumer advocates.
Published: Dec 6 2019
Biogen's CTAD Presentation On Aducanumab Elicits Mixed ResponseShow More..
Biogen Inc's (NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has drawn a mixed response. In late October, Biogen announced plans to revive its Alzheimer's program following a new analysis conducted by the …
Published: Dec 5 2019